Identification and Characterization of Potential Drug Targets and Biomarkers

Target Name: IRAG1

NCBI ID: G10335

IRAG1

Other Name(s): IRAG1 variant 1 | Protein MRVI1 | Inositol 1,4,5-triphosphate receptor associated 1 | MRVI1 | JAW1-related protein MRVI1 | inositol 1,4,5-triphosphate receptor associated 1 | IRAG1_HUMAN | inositol 1,4,5-triphosphate receptor-associated cGMP kinase substrate | Inositol 1,4,5-triphosphate receptor associated 1, transcript variant 2 | inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate | Inositol 1,4,5-triphosphate receptor-associated cGMP kinase substrate | IP3R-associated cGMP kinase substrate | IRAG1 variant 2 | JAW1L | murine retrovirus integration site 1 homolog | Inositol 1,4,5-triphosphate receptor associated 1, transcript variant 1 | Inositol 1,4,5-triphosphate receptor associated 1 (isoform a) | Inositol 1,4,5-triphosphate-associated cGMP kinase substrate | Inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate | IRAG | Inositol 1,4,5-triphosphate receptor associated 1 (isoform d)

Identification and Characterization of Potential Drug Targets and Biomarkers

The identification and characterization of potential drug targets and biomarkers is a crucial aspect of drug development. Drug targets are molecules that are involved in the regulation of cellular processes and are targeted by drugs to modulate those processes. Biomarkers are molecules that are derived from biological systems and can be used as indicators of disease or drug response. The identification and characterization of drug targets and biomarkers is a critical step in the drug development process and has a significant impact on the success of drug treatments.

IRAG1 (IRAG1 variant 1) is a protein that has been identified as a potential drug target and biomarker. IRAG1 is a key regulator of the insulin-like growth factor (IGF) signaling pathway, a critical pathway that regulates cellular processes such as cell growth, differentiation, and survival. The IGF signaling pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival. Therefore, IRAG1 is a potential drug target that could be targeted by drugs that modulate the IGF signaling pathway.

IRAG1 is a 21-kDa protein that is expressed in many tissues and cells. It is a key regulator of the IGF signaling pathway, and its function is to regulate the activity of the IGF receptor. The IGF receptor is a transmembrane protein that is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. The IGF signaling pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival. Therefore, IRAG1 is a potential drug target that could be targeted by drugs that modulate the IGF signaling pathway.

IRAG1 is a versatile protein that can be used as a drug target or biomarker. Its function as a regulator of the IGF signaling pathway makes it an attractive target for drug development. The IGF signaling pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival. Therefore, drugs that target IRAG1 and modulate the IGF signaling pathway have the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and diseases associated with uncontrolled cellular growth.

IRAG1 has been shown to be involved in many cellular processes, including cell growth, differentiation, and survival. It is a key regulator of the IGF signaling pathway, and its function is to regulate the activity of the IGF receptor. The IGF receptor is a transmembrane protein that is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. The IGF signaling pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival. Therefore, IRAG1 is a potential drug target that could be targeted by drugs that modulate the IGF signaling pathway.

IRAG1 has been shown to play a role in many diseases, including cancer, neurodegenerative diseases, and diseases associated with uncontrolled cellular growth. For example, IRAG1 has been shown to be involved in the regulation of cancer cell growth and survival. Studies have shown that IRAG1 can inhibit the growth of cancer cells and survive in an environment that is unfavorable for their growth. Therefore, drugs that target IRAG1 and modulate the IGF signaling pathway have the potential to treat a wide range of diseases, including cancer.

IRAG1 has also been shown to play a role in the regulation of neurodegenerative diseases. Studies have shown that IRAG1 is involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, drugs that target IRAG1 and modulate the IGF signaling pathway have the potential to treat neurodegenerative diseases.

IRAG1 has also been shown to play a role in the regulation of diseases associated with uncontrolled cellular growth. Studies have shown that IRAG1 is involved in the regulation of diseases associated with uncontrolled cellular growth, including

Protein Name: Inositol 1,4,5-triphosphate Receptor Associated 1

Functions: Plays a role as NO/PRKG1-dependent regulator of IP3-induced calcium release; its phosphorylation by PRKG1 inhibits bradykinin and IP3-induced calcium release from intracellular stores. Recruits PRKG1 to the endoplasmic reticulum and may mediate the assembly of PRKG1 and ITPR1 in a macrocomplex. Involved in PRKG1 signaling cascade leading to inhibition of platelet activation and aggregation. Mediates also NO-dependent inhibition of calcium signaling in gastrointestinal smooth muscle contributing to NO-dependent relaxation

The "IRAG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IRAG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets